Immunotherapy is a way of treating patients by boosting their immune system so that it fights off cancer cells. So far, clinical trials of immunotherapy for mesothelioma have produced mixed results with scientists split over whether they believe there is a future for the treatment in this area.
However, in this video from OncLiveTV, Dr. Raffit Hassan from the National Cancer Institute explains two reasons why patients with malignant pleural mesothelioma should be hopeful for the future of immunotherapy. Dr. Hassan talks about two particular drugs which are showing promise in clinical trials. In addition, clinical trials for immune checkpoint blocking antibodies has seen long-lasting tumors shrinkage for 15 to 20 percent of patients with mesothelioma.
Report on mesothelioma immunotherapy suggests a future in combination approaches. Read more here.
Mesothelioma Research News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
